AU2015350241B2 - Onapristone extended-release compositions and methods - Google Patents

Onapristone extended-release compositions and methods Download PDF

Info

Publication number
AU2015350241B2
AU2015350241B2 AU2015350241A AU2015350241A AU2015350241B2 AU 2015350241 B2 AU2015350241 B2 AU 2015350241B2 AU 2015350241 A AU2015350241 A AU 2015350241A AU 2015350241 A AU2015350241 A AU 2015350241A AU 2015350241 B2 AU2015350241 B2 AU 2015350241B2
Authority
AU
Australia
Prior art keywords
onapristone
extended
release
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015350241A
Other languages
English (en)
Other versions
AU2015350241A1 (en
Inventor
Stefan PRONIUK
Alexander ZUKIWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Context Biopharma Inc
Original Assignee
Context Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Context Biopharma Inc filed Critical Context Biopharma Inc
Publication of AU2015350241A1 publication Critical patent/AU2015350241A1/en
Assigned to CONTEXT BIOPHARMA INC. reassignment CONTEXT BIOPHARMA INC. Request for Assignment Assignors: ARNO THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2015350241B2 publication Critical patent/AU2015350241B2/en
Priority to AU2021218093A priority Critical patent/AU2021218093A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015350241A 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods Ceased AU2015350241B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021218093A AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080868P 2014-11-17 2014-11-17
US62/080,868 2014-11-17
PCT/US2015/060940 WO2016081383A1 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021218093A Division AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Publications (2)

Publication Number Publication Date
AU2015350241A1 AU2015350241A1 (en) 2017-05-04
AU2015350241B2 true AU2015350241B2 (en) 2021-05-20

Family

ID=56014429

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015350241A Ceased AU2015350241B2 (en) 2014-11-17 2015-11-16 Onapristone extended-release compositions and methods
AU2021218093A Abandoned AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021218093A Abandoned AU2021218093A1 (en) 2014-11-17 2021-08-18 Onapristone Extended-Release Compositions And Methods

Country Status (11)

Country Link
US (3) US10786461B2 (enExample)
EP (1) EP3247362A4 (enExample)
JP (1) JP6655075B2 (enExample)
KR (1) KR20170084086A (enExample)
CN (2) CN106999501B (enExample)
AU (2) AU2015350241B2 (enExample)
CA (1) CA2966753A1 (enExample)
HK (1) HK1246653A1 (enExample)
MX (1) MX391191B (enExample)
RU (1) RU2017112748A (enExample)
WO (1) WO2016081383A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143754A (en) * 1994-10-24 2000-11-07 Schering Aktiengesellschaft Competitive progesterone antagonist for demand-oriented female birth control
US20130018027A1 (en) * 2010-03-22 2013-01-17 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US20140271819A1 (en) * 2013-03-12 2014-09-18 Stefan Proniuk Onapristone polymorphic forms and methods of use

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8502612A1 (es) 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
DE3321826A1 (de) 1983-06-15 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
US4742000A (en) 1986-05-02 1988-05-03 University Of Chicago Antibody to human progesterone receptor and diagnostic materials and methods
DE3630030A1 (de) 1986-09-01 1988-03-03 Schering Ag 13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5283190A (en) 1989-07-31 1994-02-01 Traish Adbulmaged M Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
DE4008584A1 (de) 1990-03-15 1991-09-26 Schering Ag Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
CN1053450C (zh) 1992-11-19 2000-06-14 北京第三制药厂 17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5759577A (en) 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US5962444A (en) 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
AU6469601A (en) 2000-05-19 2001-12-03 Genentech Inc Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
UY26966A1 (es) 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
US7381976B2 (en) 2001-03-13 2008-06-03 Triton Thalassic Technologies, Inc. Monochromatic fluid treatment systems
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7105642B2 (en) 2001-08-03 2006-09-12 Cell Signalling Technology, Inc. Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
US20040121304A1 (en) 2001-12-21 2004-06-24 Ulrike Fuhrmann Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
PT1768625E (pt) 2004-07-09 2011-04-18 Hra Pharma Lab Composições de libertação sustida contendo moduladores do receptor da progesterona
WO2006036726A1 (en) 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2006111856A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20070167971A1 (en) 2006-01-17 2007-07-19 Raymond Huey Devices and methods for promoting the formation of blood clots in esophageal varices
US20070166372A1 (en) 2006-01-19 2007-07-19 Mai De Ltd. Preparation of solid coprecipitates of amorphous valsartan
EP1989217B1 (en) 2006-02-17 2012-06-27 Janssen Pharmaceutica N.V. 11-phosphorous steroid derivatives useful as progesterone receptor modulators
DE102006054535A1 (de) 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
CN101668739A (zh) 2007-04-24 2010-03-10 帝斯曼知识产权资产管理有限公司 用于制造前维生素d的光化学方法
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
HUE027696T2 (en) * 2007-10-12 2016-10-28 Novartis Ag Preparations containing sphingosine-1-phosphate (S1P) receptor modulators
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
JP2011511011A (ja) 2008-02-05 2011-04-07 ハーバー バイオサイエンシーズ，インコーポレイテッド 医薬的固体状態形態
TW201002736A (en) 2008-04-28 2010-01-16 Repros Therapeutics Inc Compositions and methods for treating progesterone-dependent conditions
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
WO2010110086A1 (ja) 2009-03-27 2010-09-30 株式会社小松製作所 作業車両の省燃費制御装置および作業車両の省燃費制御方法
US9074002B2 (en) 2009-04-27 2015-07-07 Cold Spring Harbor Laboratory PTP1B inhibitors
WO2010141485A1 (en) 2009-06-01 2010-12-09 Samuel Waxman Cancer Research Foundation Compositions and methods to induce differentiation and growth inhibition in breast cancer
PT2454266E (pt) 2009-07-15 2013-10-10 Cell Therapeutics Inc Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
US20110293511A1 (en) * 2009-09-29 2011-12-01 Terrance Grant Johns Specific binding proteins and uses thereof
US8261855B2 (en) * 2009-11-11 2012-09-11 Flanders Electric, Ltd. Methods and systems for drilling boreholes
WO2011084513A2 (en) 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP3702460A1 (en) 2010-11-12 2020-09-02 The General Hospital Corporation Polycomb-associated non-coding rnas
EP2651400B2 (en) 2010-12-16 2023-01-18 Amgen (Europe) GmbH Controlled release oral dosage forms of poorly soluble drugs and uses thereof
EP2655621B1 (en) 2010-12-20 2018-05-23 The General Hospital Corporation Polycomb-associated non-coding rnas
US20140079722A1 (en) 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
PH12013501837A1 (en) * 2011-03-11 2013-11-18 Celgene Corp Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases
US9618512B2 (en) 2011-04-15 2017-04-11 J-Pharma Co., Ltd. Biomarker for breast cancer
BR112013029212B1 (pt) 2011-05-13 2020-05-19 Ganymed Pharmaceuticals Ag anticorpos para o tratamento de câncer expressando claudina-6
CN103957920B (zh) 2011-10-04 2018-04-20 因维维斯制药公司 用于鉴定和治疗抗黄体制剂敏感性肿瘤的方法和系统
BR112014013709A2 (pt) 2011-12-08 2017-08-22 Fund Sales Métodos, composições farmaceuticas, e kits, para tratar cânceres resitentes às antiprogestinas
US20130338016A1 (en) 2012-04-17 2013-12-19 Vala Sciences, Inc. Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
HK1208057A1 (en) 2012-04-27 2016-02-19 Regents Of The University Of Minnesota Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
JP2015529808A (ja) 2012-07-24 2015-10-08 シーダーズ−サイナイ メディカル センター 肺癌を有する患者における化学療法に対する耐性を検出するための新規の方法
WO2014093918A1 (en) 2012-12-13 2014-06-19 Warsaw Orthopedic, Inc. Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
US20140363425A1 (en) 2013-03-13 2014-12-11 J. Dinny Graham Systems and methods for identifying cancers having activated progesterone receptors
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CN103483449A (zh) 2013-08-20 2014-01-01 东北农业大学 两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
WO2015157343A1 (en) 2014-04-08 2015-10-15 Arno Therapeutics, Inc. Systems and methods for identifying progesterone receptor subtypes
KR20170084086A (ko) 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
US10053485B2 (en) 2015-03-23 2018-08-21 Evestra, Inc. Cytotoxic agents that preferentially target leukemia inhibitory factor (LIF) for the treatment of malignancies and as new contraceptive agents
US10308676B2 (en) 2015-09-25 2019-06-04 Context Biopharma Inc. Methods of making onapristone intermediates
JP2019503353A (ja) 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
WO2017165315A1 (en) 2016-03-21 2017-09-28 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
US11597763B2 (en) 2016-05-02 2023-03-07 Tetragenetics, Inc. Anti-Kv1.3 antibodies, and methods of production and use thereof
WO2018067198A1 (en) 2016-10-03 2018-04-12 The Regents Of The University Of California Inhibitory antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143754A (en) * 1994-10-24 2000-11-07 Schering Aktiengesellschaft Competitive progesterone antagonist for demand-oriented female birth control
US20130018027A1 (en) * 2010-03-22 2013-01-17 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US20140271819A1 (en) * 2013-03-12 2014-09-18 Stefan Proniuk Onapristone polymorphic forms and methods of use

Also Published As

Publication number Publication date
MX2017005163A (es) 2018-01-18
EP3247362A4 (en) 2018-10-10
RU2017112748A (ru) 2018-12-19
EP3247362A1 (en) 2017-11-29
AU2021218093A1 (en) 2021-09-09
US20160166583A1 (en) 2016-06-16
HK1246653A1 (zh) 2018-09-14
CN106999501A (zh) 2017-08-01
MX391191B (es) 2025-03-21
US20230157960A1 (en) 2023-05-25
JP6655075B2 (ja) 2020-02-26
RU2017112748A3 (enExample) 2019-06-26
JP2017537883A (ja) 2017-12-21
CN113559075A (zh) 2021-10-29
US20210220279A1 (en) 2021-07-22
US10786461B2 (en) 2020-09-29
US11672762B2 (en) 2023-06-13
CN106999501B (zh) 2021-08-13
KR20170084086A (ko) 2017-07-19
WO2016081383A1 (en) 2016-05-26
AU2015350241A1 (en) 2017-05-04
CA2966753A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
US20230157960A1 (en) Onapristone extended-release compositions and methods
Nguyen et al. Evaluation of the effect of food and gastric pH on the single‐dose pharmacokinetics of cabozantinib in healthy adult subjects
CN103648487B (zh) 药物递送系统
US20220323446A1 (en) Sotorasib dosing regimen
JP2024519060A (ja) ソトラシブ投与レジメン
US20230270744A1 (en) Methods of Administering Elagolix
US20250017932A1 (en) Methods of Administering Elagolix
HK40062842A (en) Onapristone extended-release compositions and methods
WO2023049363A1 (en) Sotorasib and afatinib for treating cancer comprising a kras g12c mutation
WO2022261025A1 (en) Methods of treating cancer with a combination of sotorasib and trametinib
CN114340625A (zh) 用雌激素受体-α抑制剂的口服剂型治疗癌症的方法
TW202444376A (zh) 治療癌症之方法
TW202206074A (zh) 藥物配製物
HK40126893A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
WO2024005634A1 (en) Anti-angiogenic therapy as treatment for benign uterine disorders
HK40102675A (zh) 索托拉西布给药方案

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CONTEXT BIOPHARMA INC.

Free format text: FORMER APPLICANT(S): ARNO THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired